Topic: Dose Justification Across Development Phases

Reconciling Different Phase 2 and Phase 3 Endpoints

Quantifying Target-Dose Uncertainty With Profile Likelihood

Pooling Dose-Response Evidence Across Phase 2 Trials

Model Averaging for Dose-Response Decisions

Inverting Emax Models to Find Target Doses

Justifying a Dose When Efficacy and Safety Favor Different Doses

Justifying a Phase 3 Dose Without a Clear Plateau

Interpreting Dose-Response Trends in Confirmatory Trials

Interpreting Emax Parameters for Dose Selection

Interpreting Flat Dose-Response Curves